Do Not Buy Another AI Stock Before Seeing This (From Brownstone Research)

Rocket Lab (NASDAQ: RKLB) just delivered the news its shareholders least wanted to hear. On Oct. 14, the company announced that the inaugural launch of Neutron, its much-anticipated medium-lift rocket, has been moved from Q4 2026 to 2027. And the market's reaction was brutal. Shares of Rocket Lab fell almost 7% on Oct. 15, closing at $55.25 after dropping as much as 16% intraday.

For a stock that has ridden the promise of Neutron for years, this was a gut punch, and the stock’s technical positioning tells the story.

Another Neutron Delay Raises the Stakes for Rocket Lab

To understand why investors reacted so harshly, you have to understand what Neutron represents. Electron, Rocket Lab's small-lift workhorse, has made the company the clear leader in dedicated small launch. But Neutron would open the door to the far larger, more lucrative medium-lift market, putting Rocket Lab in a position to compete for the biggest commercial and national-security missions. In that regard, Neutron is the single most important driver of the company's long-term growth story, and the entire bull case hinges on it getting to the pad.

The latest delay stems from a manufacturing issue: defects were found in the forward propellant dome of the rocket's first-stage tank. Rocket Lab says it has resolved the problem, but investigating and correcting the manufacturing process pushed the timeline back.

The trouble is, this isn't the first delay. Neutron's debut has been pushed back multiple times since its early 2021 announcement, and each slip chips away at investor patience and raises questions about execution. Compounding the concern, management has previously flagged that cash-flow positivity and overall profitability depend heavily on the timing of that first successful Neutron launch, so every delay pushes the company's path to profitability further out.

The Breakdown Below $60 Adds to Rocket Lab's Technical Pressure

The chart makes the disappointment visually clear. The sell-off drove Rocket Lab decisively below the key $60 level, a zone that had been acting as major support. That $60 area marked the neckline of a head-and-shoulders pattern forming on the higher timeframe, and a confirmed break below that neckline is a classic bearish technical signal.

With that level now broken, the stock sits comfortably below all of its key moving averages and, for now, below that major $60 support. The technical structure has shifted from the coiled, base-building setup of recent months to something far more precarious. Until Rocket Lab can reclaim $60 and stabilize, the near-term momentum clearly favors the bears, and the broken neckline leaves the chart vulnerable to further downside.

Wall Street Cuts Targets But Remains Largely Bullish

The analyst community moved quickly after the news, and reactions were mixed. The biggest move came from KeyCorp, whose analyst cut the price target to $100 from $135 while maintaining an Overweight rating. Even after that sizable cut, the target still implied substantial upside from the stock's closing price.

Others largely held their ground. On the same day, TD Cowen reiterated a Buy rating with a $90 target, Cantor Fitzgerald reiterated its stance with a $122 target, and Roth Capital reaffirmed its Buy rating on the name. Not everyone was bullish, however. Weiss Ratings reiterated its Sell rating, reminding investors that not everyone is convinced the long-term story justifies the valuation, even after the pullback.

The overall takeaway is that analysts have largely maintained their positive ratings, even as some have substantially reduced their price targets. Still, the lone Sell rating underscores that the delay has given the skeptics fresh ammunition. Across all 23 analysts covering the stock, the consensus remains a Moderate Buy, with an average price target of $104.05, still implying significant upside from current levels.

Neutron's Success Remains Rocket Lab's Biggest Test

The Neutron delay is a genuine setback, and the market was right to take it seriously. A repeatedly delayed catalyst, a broken technical level, and a further delayed path to profitability are not things investors can simply shrug off. Yet the longer-term picture is more nuanced than the one-day plunge suggests. Rocket Lab still boasts a record backlog of $2.36 billion reported in Q2, a thriving Electron business, a shareholder-approved Iridium acquisition that is still pending completion, and an analyst community that, despite trimming targets, remains broadly in its corner.

The company insists Neutron will be a game-changer, and the backlog supports that belief. But after yet another delay, the burden of proof has shifted squarely onto execution. For now, investors are left watching that $60 level and waiting for Rocket Lab to prove the rocket can ultimately fly.

Read this article online ›